Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)
Status:
Completed
Trial end date:
2015-04-02
Target enrollment:
Participant gender:
Summary
Blood samples will be obtained from newly diagnosed GBM patients treated with combined
radiotherapy (RT), temozolomide (TMZ) and bevacizumab (BEV) at specific time points. The
primary outcome is the shift in T reg cell fraction a defined by determining the proportion
of CD4 cells that are CD4+ CD25.